Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Program for Anemia in AIDS Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002022
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1991

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002022 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment Program for Anemia in AIDS Patients
Treatment Program for Anemia in AIDS Patients

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • HIV Infections
  • Cytopenias
Drug: Epoetin alfa
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

  • A clinical diagnosis of AIDS.
  • Hematocrit < 30 percent.
  • Endogenous serum erythropoietin level = or < 500 U/ml.
  • A life expectancy = or > 3 months.
  • > Grade 4 performance score.
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002022
004G, I88-083
Not Provided
Not Provided
R W Johnson Pharmaceutical Research Institute
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
February 1991

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP